CRISPR Gene Editing Successfully Treats Sickle Cell Disease in Clinical Trial

A groundbreaking clinical trial has demonstrated that CRISPR gene editing can completely cure sickle cell disease in patients. The treatment, which involves editing the patients own blood stem cells, has shown a 100% success rate with no serious side effects reported. This represents the first FDA-approved CRISPR therapy for a genetic disease and opens the door for treating thousands of other genetic disorders. The therapy works by correcting the genetic mutation that causes sickle cell disease, allowing patients to produce healthy red blood cells.